Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Zubeida Jaffer short film to feature on SABC3
2014-10-08

 

Zubeida Jaffer
Photos: Adrian Steirn, 21 Icons South Africa

The nation-building initiative known as 21 ICONS South Africa, was recently thrilled to announce that Zubeida Jaffer will feature in their second season due to her professional excellence as a journalist and author.

Jaffer is a well-known South African reporter and author and has been a writer-in-residence at the UFS for three years now. The 21 ICONS project was inspired by Nelson Mandela and has created a movement for positive change. By sharing the stories of iconic South African men and women, the intention is to inspire new generations to follow in their footsteps.

One icon is featured per week in a visual celebration of engaging and entertaining portraits and short films, along with an essay biography across multiple media platforms such as print, broadcast, outdoor and social media. Jaffer’s short film will be broadcasted on 2 November 2014 at 20:27 on SABC3 and her collectable portrait will be published in City Press on the same day.

Jaffer’s short film discusses her truth as a journalist and activist who was a key figure in the struggle movement in the Western Cape during apartheid. In an intimate conversation with Adrian Steirn (creator, photographer and director of 21 ICONS, Jaffer talks about her journey as a journalist who always seeks to uncover the truth and give people who don’t have a voice an outlet to express their views, opinions and thoughts.

Other iconic South Africans that have featured on 21 ICONS, were among others, Francois Pienaar (former Springbok rugby captain who won the 1995 Rugby World Cup), Pieter-Dirk Uys (satirist who used comedy and caricature to oppose the apartheid government) and Frene Ginwala (the first female speaker in the National Assembly of South Africa).

With the country celebrating 20 years of democracy, the message that everyone can do something to make a difference – which is portrayed in these powerful and inspiring stories that make up the second season of 21 ICONS – has been well-received by South Africans.

Be sure to get your City Press early and tune in on the evening of 2 November 2014 to see Jaffer’s feature on 21 ICONS.

Jaffer is also the publisher of the Journalist website (http://www.thejournalist.org.za/) launched earlier in 2014, of which the UFS is the founding member. The Journalist is “an independent, non-profit organisation working with the academic community and a range of credible online entities to make their knowledge more accessible to the wider public.”


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept